www.klinickafarmakologie.cz / Klin Farmakol Farm. 2025;39(2):122-129 / KLINICKÁ FARMAKOLOGIE A FARMACIE 129 PŘEHLEDOVÉ ČLÁNKY Retatrutid: Nový přístup v léčbě obezity, diabetu mellitu a MASLD (metabolic dysfunction-associated steatotic liver disease) 13. Fukuda M. The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity. Diabetes. 2021;70(9):1929-1937. 14. Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab. 2005;1(1):22-31. 15. Novikoff A, Müller TD. The molecular pharmacology of glucagon agonists in diabetes and obesity. Peptides. 2023;165:171003. 16. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. 17. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet Lond Engl. 2022;400(10366):1869-1881. 18. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone- -Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. 19. Heerspink HJL, Lu Z, Du Y, et al. The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity. Kidney Int Rep. 2025;S2468024925001925. 20. Eli Lilly and Company. TRIUMPH-1 [Internet]. National Library of Medicine; 2024 [cited 2024 Jul 15]. Available from: https://clinicaltrials.gov/study/NCT05929066 21. Eli Lilly and Company. TRIUMPH-2 [Internet]. National Library of Medicine; 2024 [cited 2024 Jul 15]. Available from: https://clinicaltrials.gov/study/NCT05929079. 22. Eli Lilly and Company. TRIUMPH-3 [Internet]. National Library of Medicine; 2024 [cited 2024 Jul 15]. Available from: https://clinicaltrials.gov/study/NCT05882045. 23. Eli Lilly and Company. TRIUMPH-4 [Internet]. National Library of Medicine; 2024 [cited 2024 Jul 15]. Available from: https://clinicaltrials.gov/study/NCT05931367. 24. Eli Lilly and Company. TRIUMPH-OUTCOMES [Internet]. National Library of Medicine; 2024 [cited 2024 Jul 15]. Available from: https://clinicaltrials.gov/study/NCT06383390. 25. Eli Lilly and Company. TRANSCEND-T2D-1 [Internet]. National Library of Medicine; 2024 [cited 2024 Jul 15]. Available from: https://clinicaltrials.gov/study/NCT06354660. 26. Eli Lilly and Company. TRANSCEND-T2D-2 [Internet]. National Library of Medicine; 2024 [cited 2024 Jul 15]. Available from: https://clinicaltrials.gov/study/NCT06260722. 27. Eli Lilly and Company. TRANSCEND-T2D-3 [Internet]. National Library of Medicine; 2024 [cited 2024 Jul 15]. Available from: https://clinicaltrials.gov/study/NCT06297603. 28. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. 29. Lyons SA, Beaudry JL. Synergistic Combinations of Gut- and Pancreas-Hormone-Based Therapies: Advancements in Treatments for Metabolic Diseases. Endocrinology. 2023;164(11):bqad153. 30. Heerspink HL, Lu Z, Du Y, et al. 754-P: Effect of Retatrutide on Kidney Parameters in People with Type 2 Diabetes and/ or Obesity – A Post-Hoc Analysis of Two Phase 2 Trials. Diabetes. 2024;73(Supplement_1):754-P. 31. Lilly E. A phase 2b, double-blind study to investigate the effect of LY3437943 on renal function in participants with overweight or obesity and chronic kidney disease with or without type 2 diabetes [Internet]. clinicaltrials.gov; 2023 [cited 2023 Jan 1]. Available from: https://clinicaltrials.gov. 32. Deravi M, Piszczatoski C, Phillips B, et al. The “Weight” for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity. J Pharm Technol. 2024;40(6):300-305. 33. Ray A. Retatrutide: a triple incretin receptor agonist for obesity management. Expert Opin Investig Drugs. 2023;32(11):1003-1008. 34. Apperloo EM, Gorriz JL, Soler MJ, et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat Med. 2025;31(1):278-285. 35. Newsome PN, Sanyal AJ, Engebretsen KA, et al. Semaglutide 2.4 mg in Participants With Metabolic Dysfunction- -Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Aliment Pharmacol Ther. 2024;60(11–12):1525-1533. 36. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084. 37. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023;402(10401):529-544. 38. Mokhlesi B, Masa JF, Brozek JL, et al. Evaluation and Management of Obesity Hypoventilation Syndrome. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2019;200(3):e6-24. 39. Li M, Lin H, Yang Q, et al. Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis. Sleep. 2025;48(4):zsae280. 40. Jalleh RJ, Marathe CS, Rayner CK, et al. Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility. Endocrinology. 2024;166(1):bqae155. 41. Zhang X, Wang M, Wang X, et al. Comparison of New Glucose-Lowering Drugs on the Risk of Pancreatitis in Type 2 Diabetes: A Network Meta-Analysis. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2022;28(3):333-341. 42. Khera AV, Chaffin M, Wade KH, et al. Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood. Cell. 2019;177(3):587-596.e9. 43. Salmen T, Potcovaru CG, Bica IC, et al. Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review. Pharmaceuticals. 2024;17(10):1322.
RkJQdWJsaXNoZXIy NDA4Mjc=